Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Notes Payables: 2020-2025

Historic Notes Payables for Ascendis Pharma A (ASND) over the last 4 years, with Sep 2025 value amounting to $498.3 million.

  • Ascendis Pharma A's Notes Payables rose 7.50% to $498.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $498.3 million, marking a year-over-year increase of 7.50%. This contributed to the annual value of $495.9 million for FY2024, which is 13.22% up from last year.
  • Per Ascendis Pharma A's latest filing, its Notes Payables stood at $498.3 million for Q3 2025, which was up 5.29% from $473.2 million recorded in Q2 2025.
  • Ascendis Pharma A's Notes Payables' 5-year high stood at $598.2 million during Q3 2023, with a 5-year trough of $8.0 million in Q4 2021.
  • Moreover, its 3-year median value for Notes Payables was $473.2 million (2025), whereas its average is $490.7 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Notes Payables surged by 3,591.46% in 2023, and later decreased by 22.51% in 2024.
  • Ascendis Pharma A's Notes Payables (Quarterly) stood at $8.0 million in 2021, then surged by 48.28% to $11.9 million in 2022, then surged by 3,591.46% to $438.0 million in 2023, then climbed by 11.79% to $489.6 million in 2024, then increased by 7.50% to $498.3 million in 2025.
  • Its Notes Payables was $498.3 million in Q3 2025, compared to $473.2 million in Q2 2025 and $472.9 million in Q1 2025.